Capecitabine in the treatment of colorectal cancer

Kelly, C. and Cassidy, J. (2007) Capecitabine in the treatment of colorectal cancer. Expert Review of Anticancer Therapy, 7(6), pp. 803-810. (doi: 10.1586/14737140.7.6.803)

Full text not currently available from Enlighten.

Publisher's URL: http://dx.doi.org/10.1586/14737140.7.6.803

Abstract

Capecitabine is an oral prodrug of 5-fluorouracil. It is being increasingly used in the treatment of colorectal cancer in both the adjuvant and metastatic settings. This review aims to explore the data in relation to the pharmacology and mode of action of capecitabine, followed by an in-depth review of the available clinical evidence for the use of capecitabine as a single agent, or in combination therapy, in the treatment of colorectal cancer. The pharmacoeconomic and medical resource use implications are also investigated. The future role of capecitabine in the treatment of colorectal cancer and the questions that remain to be answered with regard to its optimal use are considered.

Item Type:Articles
Keywords:Capecitabine Colorectal cancer
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Cassidy, Professor James
Authors: Kelly, C., and Cassidy, J.
Subjects:R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Research Group:Centre for Oncology & Applied Pharmacology
Journal Name:Expert Review of Anticancer Therapy
ISSN:1473-7140

University Staff: Request a correction | Enlighten Editors: Update this record